NDAORALTABLETPriority Review
Approved
Nov 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TONOCARD (tocainide hydrochloride) is an oral Class IB antiarrhythmic agent approved in 1984 for the treatment of ventricular arrhythmias. It is a lidocaine analog administered orally and works by suppressing automaticity and conduction velocity in cardiac tissue. The drug is indicated for patients with ventricular arrhythmias requiring pharmacologic management.
LOE Approaching
LOE is approaching for this legacy oral antiarrhythmic, suggesting a contracting commercial team focused on managing brand decline rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TONOCARD offers limited career growth prospects given its LOE-approaching status and legacy market position. Roles are concentrated in defensive commercial and compliance functions rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on TONOCARD at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.